MA50156A - Variants d'anticorps - Google Patents
Variants d'anticorpsInfo
- Publication number
- MA50156A MA50156A MA050156A MA50156A MA50156A MA 50156 A MA50156 A MA 50156A MA 050156 A MA050156 A MA 050156A MA 50156 A MA50156 A MA 50156A MA 50156 A MA50156 A MA 50156A
- Authority
- MA
- Morocco
- Prior art keywords
- antibody variants
- variants
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17191989.7A EP3456738A1 (fr) | 2017-09-19 | 2017-09-19 | Variantes d'anticorps |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50156A true MA50156A (fr) | 2020-07-29 |
Family
ID=59923275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050156A MA50156A (fr) | 2017-09-19 | 2018-09-11 | Variants d'anticorps |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11999781B2 (fr) |
| EP (2) | EP3456738A1 (fr) |
| JP (2) | JP7240385B2 (fr) |
| KR (1) | KR20200053514A (fr) |
| CN (1) | CN111094343A (fr) |
| AR (1) | AR113303A1 (fr) |
| AU (1) | AU2018337495A1 (fr) |
| BR (1) | BR112020005482A2 (fr) |
| CA (1) | CA3075959A1 (fr) |
| CL (1) | CL2020000721A1 (fr) |
| CO (1) | CO2020003260A2 (fr) |
| CR (2) | CR20200132A (fr) |
| EA (1) | EA202090617A1 (fr) |
| GE (1) | GEP20237484B (fr) |
| IL (1) | IL273351A (fr) |
| JO (1) | JOP20200063A1 (fr) |
| MA (1) | MA50156A (fr) |
| MX (1) | MX2020002989A (fr) |
| PH (1) | PH12020500473A1 (fr) |
| SG (1) | SG11202002220TA (fr) |
| TW (1) | TW201915021A (fr) |
| WO (1) | WO2019057564A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110072887A (zh) | 2016-08-02 | 2019-07-30 | 威特拉公司 | 工程化多肽及其应用 |
| WO2020114616A1 (fr) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2348051T (lt) * | 2003-11-05 | 2019-02-25 | Roche Glycart Ag | Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija |
| KR100971497B1 (ko) * | 2004-12-29 | 2010-07-21 | 주식회사유한양행 | 인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체 |
| BRPI0518994A2 (pt) | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| DK2235059T3 (en) | 2007-12-26 | 2015-03-30 | Xencor Inc | FC-VERSIONS OF MODIFIED BINDING TO FcRn |
| BRPI0914319B8 (pt) | 2008-06-25 | 2021-05-25 | Esbatech Alcon Biomed Res Unit | imunoligante que se liga especificamente ao tnf alfa humano e composição |
| JP6832707B2 (ja) | 2014-03-26 | 2021-02-24 | セル メディカ スイッツァランド アーゲー | ＴＮＦαに対する結合メンバー |
| EP3131926A1 (fr) | 2014-04-16 | 2017-02-22 | UCB Biopharma SPRL | Protéines fc multimères |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| US11319383B2 (en) | 2016-03-14 | 2022-05-03 | Universitetet | Oslo | Engineered immunoglobulins with altered FcRn binding |
| ES2836349T3 (es) * | 2016-03-17 | 2021-06-24 | Tillotts Pharma Ag | Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos |
-
2017
- 2017-09-19 EP EP17191989.7A patent/EP3456738A1/fr active Pending
-
2018
- 2018-09-11 WO PCT/EP2018/074522 patent/WO2019057564A1/fr active Application Filing
- 2018-09-11 BR BR112020005482-8A patent/BR112020005482A2/pt unknown
- 2018-09-11 CA CA3075959A patent/CA3075959A1/fr active Pending
- 2018-09-11 CN CN201880060497.2A patent/CN111094343A/zh active Pending
- 2018-09-11 AU AU2018337495A patent/AU2018337495A1/en active Pending
- 2018-09-11 GE GEAP201815316A patent/GEP20237484B/en unknown
- 2018-09-11 JP JP2020516456A patent/JP7240385B2/ja active Active
- 2018-09-11 CR CR20200132A patent/CR20200132A/es unknown
- 2018-09-11 MA MA050156A patent/MA50156A/fr unknown
- 2018-09-11 KR KR1020207009263A patent/KR20200053514A/ko not_active Application Discontinuation
- 2018-09-11 EA EA202090617A patent/EA202090617A1/ru unknown
- 2018-09-11 CR CR20210205A patent/CR20210205A/es unknown
- 2018-09-11 JO JOP/2020/0063A patent/JOP20200063A1/ar unknown
- 2018-09-11 SG SG11202002220TA patent/SG11202002220TA/en unknown
- 2018-09-11 US US16/648,537 patent/US11999781B2/en active Active
- 2018-09-11 EP EP18762890.4A patent/EP3684807A1/fr active Pending
- 2018-09-11 MX MX2020002989A patent/MX2020002989A/es unknown
- 2018-09-17 TW TW107132681A patent/TW201915021A/zh unknown
- 2018-09-19 AR ARP180102664A patent/AR113303A1/es unknown
-
2020
- 2020-03-09 PH PH12020500473A patent/PH12020500473A1/en unknown
- 2020-03-17 IL IL273351A patent/IL273351A/en unknown
- 2020-03-19 CO CONC2020/0003260A patent/CO2020003260A2/es unknown
- 2020-03-19 CL CL2020000721A patent/CL2020000721A1/es unknown
-
2022
- 2022-12-27 JP JP2022210008A patent/JP7402304B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA202090617A1 (ru) | 2020-07-27 |
| BR112020005482A2 (pt) | 2020-09-29 |
| US11999781B2 (en) | 2024-06-04 |
| EP3456738A1 (fr) | 2019-03-20 |
| IL273351A (en) | 2020-05-31 |
| CA3075959A1 (fr) | 2019-03-28 |
| WO2019057564A1 (fr) | 2019-03-28 |
| EP3684807A1 (fr) | 2020-07-29 |
| AU2018337495A1 (en) | 2020-04-09 |
| KR20200053514A (ko) | 2020-05-18 |
| MX2020002989A (es) | 2020-07-22 |
| AR113303A1 (es) | 2020-04-08 |
| US20200216527A1 (en) | 2020-07-09 |
| CO2020003260A2 (es) | 2020-04-13 |
| SG11202002220TA (en) | 2020-04-29 |
| CR20200132A (es) | 2020-07-24 |
| JP2023036885A (ja) | 2023-03-14 |
| JP7240385B2 (ja) | 2023-03-15 |
| JP7402304B2 (ja) | 2023-12-20 |
| JP2020534307A (ja) | 2020-11-26 |
| GEP20237484B (en) | 2023-03-27 |
| PH12020500473A1 (en) | 2021-01-25 |
| CR20210205A (es) | 2021-07-27 |
| TW201915021A (zh) | 2019-04-16 |
| JOP20200063A1 (ar) | 2020-03-17 |
| CN111094343A (zh) | 2020-05-01 |
| CL2020000721A1 (es) | 2020-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47694A (fr) | Anticorps anti-tigit | |
| MA49034A (fr) | Anticorps anti-lag3 | |
| MA49043A (fr) | Formulation stable d'anticorps | |
| MA47268A (fr) | Anticorps anti-gpc3 | |
| MA53434A (fr) | Anticorps anti-tigit | |
| MA52884A (fr) | Anticorps anti-il-11 | |
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
| MA46041A (fr) | Anticorps anti-tim -3 | |
| MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
| MA56006A (fr) | Formulations sous-cutanées d'anticorps her2 | |
| MA42924A (fr) | Variants optimisés d'anticorps anti-vegf | |
| MA44381A (fr) | Format d'anticorps hétérodimères multispécifiques | |
| MA49749A (fr) | Anticorps anti-cd137 | |
| MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
| MA45231A (fr) | Anticorps anti-ige | |
| MA52212A (fr) | Anticorps multivalent | |
| MA44054A (fr) | Plateforme d'anticorps bispécifique | |
| MA52366A (fr) | Anticorps anti-tl1a optimisés | |
| MA52152A (fr) | Anticorps | |
| MA44236A (fr) | Anticorps anti-tgfbêta 2 | |
| MA51134A (fr) | Anticorps anti-alpha-synucléine | |
| MA42843A (fr) | Anticorps anti-cd115 | |
| MA54052A (fr) | Formulation d'anticorps | |
| MA54139A (fr) | Formulation d'anticorps |